ArticleMolecular cancer therapeutics2014

Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.

Jin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.